HDT Bio Corp.

Private

Seattle, WashingtonHealthcare & Life Scienceshttps://hdt.bio

Last Round

Grant

Sep 17, 2024

Total Funding Raised

$58.75M

Momentum

Quiet

No recent growth signals

Company Overview

HDT Bio Corp. is a biotechnology company developing drugs for immunotherapy of cancers and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2G

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

self-amplifying RNAsaRNARNA vaccine platformrepRNAlipid nanoparticle deliveryLNP deliveryimmunotherapiescancer vaccinesinfectious disease vaccinesgovernment contractsnext-generation mRNAbiodefense contractsLION delivery systemvaccine developmenttechnology licensingclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HDT Bio Corp. Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

HDT Bio Corp. Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Sep 17, 2024
Grant	Jan 23, 2024
Grant	Oct 4, 2023
Grant	Nov 30, 2022
Seed	Feb 16, 2021
Seed	Oct 5, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Steven Reed

Co-Founder CEO

Founding Team

HDT Bio Corp. Investors

Notable investors and investment history

Investor	Rounds
National Institute of Allergy and Infectious Diseases	Grant
U.S. Department of Health and Human Services	Grant
U.S. Department of Defense	Grant
Public Health Emergency Medical Countermeasures Enterprise	Grant
U.S. Department of War	Grant
Johnson & Johnson Innovation - JJDC, Inc.	Grant
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense	Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 20, 2025
Developing a vaccine platform in collaboration with RML, currently in animal model evaluations.
Jan 23, 2024
$749K grant received from BARDA and PHEMCE.

View all signals

HDT Bio Corp. Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

HDT Bio Corp. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HDT Bio Corp.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington

Employee Range56

Year Founded2018

Last FundingSep 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.